Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina.
暂无分享，去创建一个
[1] I. Adewole,et al. Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. , 2010, Current HIV research.
[2] V. Calvez,et al. Factors Associated with Virological Response to Etravirine in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-1-Infected Patients , 2009, Antimicrobial Agents and Chemotherapy.
[3] L. Saravolatz,et al. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] H. Gunthard,et al. Update of the Drug Resistance Mutations in HIV-1. , 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[5] A. Jha,et al. Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance? , 2008, AIDS.